NASDAQ$GPCR
Structure Therapeutics Inc · Q3 2024 earnings
Q3 2024 earnings · · Investor relations
Briefing
Structure Therapeutics reported its financial results for the third quarter ended September 30, 2024.
Structure Therapeutics reported a net loss of $34.0 million for the third quarter of 2024. The company's cash, cash equivalents, and short-term investments totaled $915.3 million as of September 30, 2024, which is expected to fund operations through at least 2027.
- First patients dosed in Phase 2b ACCESS study of GSBR-1290 for obesity.
- Oral small molecule amylin receptor agonist development candidate expected to be selected by the end of 2024.
- Cash, cash equivalent and short-term investments of $915.3 million expected to fund projected operations and key clinical milestones through at least 2027.
- R&D expenses for the third quarter of 2024 were $32.6 million.
Headline financials
Revenue & EPS history
Structure Therapeutics · Revenue · Quarterly
$0
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 15 quarterly earnings reports · overlaid with Q3 2024
+1.2%
Avg return
Earnings day
-1.1%
Avg return
5 days after
+9.8%
Avg return
30 days after
40%
6 / 15 earnings
Positive
+14.8%
Q4 2024
Best reaction
-11.6%
Q3 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | -2.6% | -2.5% | -29.1% | |
| Q3 2025 | -2.0% | +7.3% | +3.3% | |
| Q1 2025 | -4.6% | -11.2% | -21.2% | |
| Q4 2024 | +14.8% | +13.1% | -0.6% | |
| Q3 2024 | +1.9% | -14.1% | -15.5% | |
| Q2 2024 | -0.8% | +0.9% | +8.6% | |
| Q1 2024 | -8.7% | -9.0% | +35.3% | |
| Q4 2023 | -2.5% | -5.9% | +15.1% | |
| Q3 2022 | +11.5% | +7.1% | +23.4% | |
| Q3 2023 | -11.6% | -1.6% | +7.2% | |
| Q2 2023 | -1.9% | -2.9% | -0.1% | |
| Q2 2022 | -1.9% | -2.9% | -0.1% | |
| Q1 2023 | +8.9% | +1.9% | +40.2% | |
| Q4 2022 | +8.9% | +1.9% | +40.2% | |
| Q1 2022 | +8.9% | +1.9% | +40.2% | |
| Q4 2021 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro